健康元(600380.SH)：JP-1366片药品注册上市许可申请获受理

Core Viewpoint - Health元's subsidiary, Lijun Pharmaceutical Group, has received the acceptance notice from the National Medical Products Administration for the domestic production registration of JP-1366 tablets, an innovative potassium ion competitive acid blocker (P-CAB) [1] Group 1 - JP-1366 tablets work by competitively blocking the K(+) channel of H(+), K(+)-ATPase (proton pump), inhibiting the binding of K(+) to the proton pump, and suppressing gastric acid secretion [1] - The drug promotes esophageal mucosal healing and improves reflux symptoms [1] - JP-1366 tablets can rapidly increase gastric pH levels and maintain gastric pH above 4 for an extended period, effectively addressing nighttime acid breakthrough [1]